DDIT3 and myxoid liposarcoma: To characterize for the first time the DNA binding pattern of the FUS-DDIT3 oncoprotein in myxoid liposarcoma (MLPS) tumor models, chromatin immunoprecipitation followed by sequencing assay (ChIP-Seq) was performed on ex vivo xenograft models using an antibody against the DDIT3 transcription factor.